Background: Mouse models of human disease are invaluable for determining the differentiation ability and functional capacity of stem cells. The best example is bone marrow transplants for studies of hematopoietic stem cells. For organ studies, the interpretation of the data can be difficult as transdifferentiation, cell fusion or surface antigen transfer (trogocytosis) can be misinterpreted as differentiation. These events have not been investigated in hematopoietic stem cell transplant models.
Introduction
Stem cell biology relies heavily on the specificity of surface markers as an initial determination of a cells identity after differentiation. Presentation of a predetermined set of markers characteristic of the desired cell type being investigated is required before more complex studies to determine cell function are carried out. In vitro studies can be used to determine cell function but the ability of a newly differentiated cell to successfully reverse the affects of a disease in an experimental animal model is the gold standard. Being able to identify donor cells in any animal model is critical for determining the extent and the mechanism of engraftment and differentiation.
Mouse models for bone marrow transplantation with hematopoietic stem cells (HSC) have become the paradigm for stem cells analysis since their discovery almost 50 years ago [1, 2] . With the discovery of embryonic and tissue specific stem cells, mouse models of disease are also often used to measure the differentiation and functional capacity of these cells. As with HSC transplants, embryonic or tissue specific stem cells are delivered to the diseased organ and successful engraftment and restoration of tissue function is measured post transplantation [3, 4, 5, 6] . Both intraspecies and xenograft models of disease have been successfully used to demonstrate the functional capacity of different types of human and mouse stem cells. Additionally, mouse models of human disease are ideal for determining the clinical significance of novel stem cell based therapies due to the incidence of similar transplantation issues that occur in a clinical setting such as graft rejection and, for bone marrow transplants, graft versus host disease (GvHD) [7, 8, 9, 10] .
The analysis of HSC engraftment in most cases is straightforward because the donor cells can be easily recovered from the bone marrow as single cells and their contribution is measured by antibodies to donor specific cell surface proteins using flow cytometry. For solid organ transplants such as pancreas, spinal cord or heart, the delivery of cells and their subsequent identification and recovery after transplantation is more complex. Usually, immunohistochemical analysis of solid organs is required. The difficulty of obtaining high levels of engraftment, coupled with the difficulty of tissue recovery and analysis results in few positive events. Further complicating the interpretation of the data is that differentiation events in animal models have been attributed to differentiation, transdifferentiation, cell fusion or surface antigen transfer (trogocytosis), depending on the donor cells and the animal model being used.
We were interested in determining if cell fusion or surface antigen transfer plays a role in hematopoietic cell differentiation in NOD.CB17-Prkdc SCID (NOD/SCID) mouse models. Using a standard SCID repopulating assay, we transplanted irradiated NOD/SCID mice with either the total nucleated cell (TNC) population or the donor blood cells were separated into Lineage positive (mature) cells or the Lineage minus (stem and progenitor) cells. The blood cells used were from human umbilical cord blood or human bone marrow. The use of human cells allowed us to distinguish between human cells (HLA:ABC+) and mouse cells (H2Kd+). Hybrid cells would be positive for both human and mouse antigens [11, 12] .
Cell fusion involves the fusion of cell membranes, cytoplasm and the nuclei resulting in a hybrid cell that contains chromosomes and proteins from both cells [13] . Trogocytosis involves only the transfer of cell surface antigens without the transfer of DNA or cytoplasm and transdifferentiation is defined as the ability of a differentiated cell to change phenotype to an unrelated cell without undergoing a de-differentiation step [14, 15] . In order to differentiate between cell fusion, trogocytosis or transdifferentiation it is important to investigate the chromosome content and the surface antigen composition of the cell. Xenograft models are ideal for determining the extent of these three possible processes during blood cell engraftment and differentiation. Analysis of fusion or trogocytosis will result in a mix of human and mouse components in a single cell, while transdifferentiation will not.
Despite the long time use of bone marrow transplants in both the clinical and experimental setting, fusion or trogocytosis between blood cells has not been well documented. In contrast, cell fusion has been well studied in transplantation models used to explore the possible transdifferentiation of blood cells [16, 17, 18] . Moreover, trogocytosis has not been considered in the stem cell field mainly because its mechanism is unknown and its significance has been limited to antigen presentation involved in immune reactions [19, 20, 21, 22] .
Our results reveal that the majority of engrafted human cells are indeed hybrid cells that are a result of surface antigen transfer (trogocytosis) and not cell-cell fusion. Furthermore our results demonstrate that trogocytosis is much more widespread than previously thought resulting in the transfer of host (mouse) MHC Class I and CD45 antigens to donor (human) cells. We discuss the implications of these results on the interpretation of blood cell based therapies to treat blood and non-blood disorders.
Results

Xenograft Bone Marrow Transplants Results in H2Kd+HLA+ Hybrid Cells
Irradiation of mice followed by intravenous infusion of human hematopoietic stem cells is a common model for the study of bone marrow transplantation. The use of immune compromised mice such as the NOD/SCID mouse allows for successful xenografts and has been instrumental in the development of bone marrow transplant regimes for use in patients. With reports that blood cells are capable of fusing with cells of the liver, Purkinje cells and lung cells [23] , we sought to determine if blood cells are also capable of fusing amongst themselves. We also wanted to determine the extent of trogocytosis between donor and recipient cells in a xenograft model as this process can be interpreted as a cell fusion event. The xenograft model is ideal for this study as human and mouse blood antigens can easily be distinguished using flow cytometry with species specific antibodies to MHC class I or HLA antigens followed by FISH with mouse and human specific pancentromeric probes. Flow cytometry allowed us to detect double positive cells even if their occurrence was rare. In this study we report on the results from 119 mice. TNCs, Lin-or Lin+ cells from human umbilical cord blood or human bone marrow were used for our xenograft studies. NOD/SCID mice were prepared and transplanted as per standard protocols [11, 24, 25] . Our standard engraftment time of 8-10 weeks was used in the preliminary set of results. Mice were transfused with 3.5-8 million TNCs or 150,000 Lin-cells or 150,000 Lin+ cells. Mice were assessed at 1 week post transplantation to 7 months post transplantation. All mice were assessed for human cells using an antibody against the human leukocyte antigens-A,B,C (HLA) and mouse cells using an antibody to the mouse MHC H2Kd (H2kd) antigen that is specific for NOD/SCID mice. 88% of the umbilical cord blood (UCB) -transplanted mice (76/86) were positive for HLA+ cells and all of these positive mice (76/76) contained hybrid cells (H2Kd+HLA+) ( Figure 1A ). IgG negative controls (mouse: TNC, 2 months) and sham treated mice (mouse: HBSS, 2 months) were always negative for HLA antibody reactions (n = 8) ( Figure 1B ). Mice that received Lin+ cells (n = 12) were also negative for HLA-ABC staining. For all positively engrafted animals except one, .80% of the human cells (HLA+) isolated from the recipient mouse bone marrow co-expressed mouse H2Kd antigen (HLA+H2Kd+). One mouse transplanted with human UCB cells and assayed at 5 months had a high level of human blood cell engraftment (82%) and was the only mouse where the majority of human cells did not also contain the mouse H2Kd antigen. It is possible that the high percentage of human cells meant that the mouse cells available for fusion or trogocytosis were limited.
Human bone marrow was also tested using the same transplant conditions (n = 13), with mice assessed at 1 and 2 months. Engraftment occurred in 11/13 mice and hybrid cells were also observed in all engrafted mice (representative mouse: Figure 1A , last panel, 2 month data).
The H2Kd and HLA-ABC antibodies used in this study were tested for cross species reactions and non-specific reactions using either mouse BM or human UBC blood or a 50:50 mixture of mouse and human blood cells ( Figure S1 ). Results indicate that the anti-HLA antibody only bound human cells while the anti-H2Kd antibody only bound mouse cells as expected. All other mouse or human specific antibodies used in this study were also tested for non-specific binding and demonstrated species specificity (data not shown).
FISH Analysis Reveals That Trogocytosis and Not Fusion
Occurs between Human and Mouse Blood Cells in the Xenograft Model and That the Transfer of HLA/MHC Class I Antigens Is Unidirectional
The observation of such high levels of hybrid cells post engraftment was unexpected. Our hypothesis was that fusion or antigen transfer between blood cells may occur but we did not expect to observe nearly 100% involvement of the donor cells. Therefore, we sought to confirm if the mechanism is cell fusion and/or trogocytosis through fluorescent in situ hybridization (FISH). Pan-centromeric species-specific probes were used to ensure the random loss of some chromosomes that can occur in cell hybrids would not produce a false negative result. Post transplant bone marrow cells that were HLA+H2Kd+ (hybrid) HLA+H2Kd-(human only) or HLA-H2Kd+ (mouse only) were collected by FACS and subjected to FISH (Figure 2 ). The hybrid cells (H2Kd+HLA+) and the cells with HLA but not H2Kd, contained only human chromosomes and the non-hybrid mouse cells (H2Kd+HLA-) from the same mice were positive for mouse chromosomes only. Mouse bone marrow and human UCB cells were used to confirm that the mouse and human probes were species specific and that no cross reaction or non-specific reactions occurred. Karyotyping of the H2Kd+HLA+ cells confirmed our FISH results that only human chromosomes were present (data not shown).
The positive results we obtained showing the presence of both human and mouse surface antigens without the presence of mouse chromosomes strongly indicate that cell surface antigens are capable of transferring from one cell to another. Our FISH results confirm that trogocytosis is unidirectional as the H2Kd+HLA+ hybrid cells only contained human chromosomes. This result shows that the human cells acquired mouse surface proteins through trogocytosis. If trogocytosis also occurred in the other direction (human antigens to mouse cells) then we would have observed hybrid cells containing mouse chromosomes. Taken together, this data demonstrates that the donor human cells acquire the recipient mouse MHC antigens through trogocytosis and not fusion.
CD45 Is Involved in Trogocytosis and Is Capable of BiDirectional Transfer
Since the bone marrow contains mostly CD45+ blood cells, it is conceivable that the CD45 antigen may be involved in trogocytosis. Although the bone marrow is comprised mainly of CD45+ blood cells we cannot assume that all of the HLA+H2Kd+ hybrid cells are also CD45+. A subset of the mice engrafted with human blood cells that were analysed for HLA+H2Kd+ cells were also examined for mouse CD45 and human CD45 to determine if these surface antigens are involved in trogocytosis. In the previous experiments we determined that H2kd is transferred to the donor human cells but there is no reciprocal transfer with HLA to mouse cells. For the experiments done here, the bone marrow cells from engrafted mice were stained with H2Kd-PE, HLA-FITC and CD45-APC (either mouse or human) (n = 16 with UCB and n = 8 with human bone marrow: 1-4 months post transplantation). All mice studied showed similar results. The representative data in Figure 3 was from a mouse that received UCB TNC and was analysed 2 months post transplantation. This mouse has 15% HLA+ cells of which 12% are H2Kd+HLA+ (Figure 3Ai ). We observed that only 2% of the HLA positive cells were also mouse CD45+ ( Figure 3Aii ) and these cells are also positive for H2Kd (H2Kd+HLA+mouseCD45+) (Figure 3Aiii ). Since H2Kd is transferred to human cells at a high frequency, these H2Kd+HLA+mouse CD45+ cells are most likely due to both mouse CD45 and H2Kd being transferred to the human cells and that mouse CD45 transfer occurs at a much lower frequency than for H2Kd.
When the bone marrow cells from the same mouse was stained for human CD45 we observed more human CD45+ cells than HLA+ cells (20% versus 15%) (Figure 3Bi ) indicating that some of the human CD45+ cells must be HLA negative. This was confirmed when the same bone marrow cells interrogated for human CD45 and HLA. Approximately 4% of the human CD45+ cells were HLA negative ( Figure 3Bii ). HLA+humanCD45+ cells were investigated for H2Kd revealing that 91% were triple positive ( Figure 3Biii ) confirming that H2Kd is transferred to the human blood cells. When the 4% HLA-humanCD45+ cells were examined for the presence of H2Kd antibody, we could demonstrate that 98% of these cells have H2Kd on their surface ( Figure 3Biv ). There are two possible explanations for our observation. It is possible that H2Kd transferred to the huCD45 cells and at the same time these cells lost their HLA antigens but this is unlikely and the more parsimonious explanation is that human CD45 is capable of transferring to mouse bone marrow cells. Taken together the data reveals that CD45 is capable of bidirectional transfer although at a low frequency.
Bone marrow cells from mice engrafted with human cells were simultaneously stained with anti-mouseCD45 and anti-humanCD45. Cells that were mouseCD45+humanCD45-versus mouseCD45+human CD45+ had higher PE-fluorescent intensity (mouseCD45: Y-axis) indicating that they contained more mouse CD45 antigen/cell ( Figure 3Ci ). Because fluorescence intensity is directly proportional to the amount of antigen on the cell surface, this suggests that the hybrid cells (mouseCD45+humanCD45+) will regulate their total CD45 antigen levels by down regulating mouse CD45 due to the presence of human CD45 on the surface. A similar result was observed for peripheral blood cells ( Figure 3Cii ).
Trogocytosis Is Not Due to Donor Macrophages
Trogocytosis has been reported to involve antigen presenting cells such as macrophages. Therefore, we investigated the extent that macrophages, which express CD14, may contribute to our observations. No HLA+ or human CD14+ cells were detected in non-engrafted mice (negative control) (Figures 4Ai, Aii). Mouse CD14+ cells were observed as expected (Figure 4Aiii ). In positively engrafted mice double positive H2Kd+HLA+ bone marrow cells were observed (Figure 4Bi ). When the bone marrow from these mice were co-stained for H2Kd and human CD14, all of the human CD14+ cells were also positive for H2Kd antigen as expected as H2Kd transfers readily to the human cells (Figure 4Bii ). Since the humanCD14+H2Kd+ cells represent a subset comprising only 7.2% of the of the hybrid cells (H2kd+HLA+), this indicates that phagocytosis by human macrophages are not solely responsible for the high rate of H2Kd+/HLA+ hybrid cells observed in the grafts. However, we cannot discount that macrophage phagocytosis is not the mechanism responsible for the appearance of this small subset of huCD14+/H2Kd+ hybrid cells. Figure 4Biii reveals that none of the HLA+ cells were positive for mouse CD14 indicating that mouse CD14 is not transferred to human cells.
Platelets Are Not Involved in Trogocytosis Events
Previous studies have indicated that trogocytosis is specific to Tcells and antigen presenting cells, yet the data presented in this study indicates that many different blood cells are involved. We investigated if platelets are involved in the trogocytosis in our model by investigating if the CD41a antigen is transferred from the recipient cells to donor cells. Platelets are a fairly abundant cell type found in the bone marrow and should provide sufficient antigen (CD41a) to be involved in trogocytosis. Using the same mice used for CD14 detection, mouse CD41a+ cells were detected in the non-engrafted mouse (negative control) but no HLA+ cells were present, as expected ( Figure 4Ci ). However, engrafted mice did not contain any human CD41a+ cells (Figure 4Cii ), indicating the human UCB cells were not capable of differentiating into platelets in our SRC assay. Therefore, we could not conclude if H2Kd is transferred to human platelets. Engrafted mice stained with antibodies to HLA and mouse CD41a indicate that as observed for mouse CD14, mouse CD41a does not transfer to human cells as no double positive cells were observed ( Figure 4Ciii ). This result suggests that not all recipient blood cells are involved and that trogocytosis is regulated in the xenograft model rather than occurring due to the close association of randomly paired cells.
Location and Timing of Trogocytosis Indicates a Role for the Bone Marrow and Reveals the Involvement of Hematopoietic Stem and Progenitor Cells
In this report all donor cells were injected into the tail vein of the mice, which requires migration of these cells to the bone marrow in order to achieve long-term engraftment. It is possible that the donor cells encounter recipient cells in the peripheral blood (PB) where trogocytosis could occur between mature blood cells. In order to determine if the PB is the location of trogocytosis, we analysed peripheral blood from a subset of the animals presented in Figure 1 . We tested animals transplanted with Lincells or Lin+ cells and could not detect human cells (HLA+) in the peripheral blood at 7 or 9 days post transplantation, but were able to observe human cells in the PB from 1 month to 7 months post transplantation mice ( Figure 5A ). The PB results for the 1-7 month post transplantation group were identical to that observed with their bone marrow cell analysis (Compare to Figure 1 ). The absence of human cells or hybrid cells in the PB of animals given Lin-or Lin+ cells at days 7 and day 9 post transplantation suggests that trogocytosis does not occur in the peripheral blood. Coupled with the observation that when the Lin+ are transplanted no hybrid cells are ever observed, suggests the trogocytosis occurs in the bone marrow.
Because trogocytosis occurs after the migration of donor cells to the bone marrow, this suggests stem and progenitor cell involvement. We tested for this using FACS, CFU and LTC-IC assays. First, we tested for the transfer of H2Kd to human CD34+ cells in engrafted NOD/SCID mice. Human CD34+ cells in the SCID repopulating assay represent a rare population. 4-months post transplantation bone marrow was flushed from a mouse transplanted with 1610 8 human TNC cells. The mouse was positive for human CD34+ hi cells (0.14%) and 89% of these cells were also H2Kd+ indicating the transfer of mouse H2Kd to human CD34+ cells ( Figure 5B ). The CFU assay allowed use to confirm that hematopoietic progenitor cells are part of the hybrid cell (H2Kd+HLA+) population and also allowed us to confirm that trogocytosis and not cell fusion is the means for hybrid cell production. It is possible that a cell-cell fusion event could result in the translocation of the mouse H2Kd gene to a human chromosome, which results in the expression of the H2Kd protein on the hybrid cells. These translocation events would not be detected by our FISH analysis using centromeric probes. To confirm that the mouse:human hybrid cells did not contain any mouse DNA flow cytometry sorted and collected H2Kd+HLA+ cells were grown in CFU cultures that allowed the cells to undergo proliferation. Cell proliferation will result in the loss of H2Kd antigen on the cell surface if there is no mouse gene present to be transcribed. H2Kd+HLA+ cells were grown in CFU medium containing either mouse recombinant growth factors or human recombinant growth factors for 18 days. Control unsorted BM cells from mice that did not receive any human cells grew in medium with recombinant mouse growth factors but not in CFUs with human factors, while human UCB cells grew in both media (n = 2, each condition). Mouse-derived H2Kd+HLA+ cells were collected from mice at 2 weeks, 4 months or 5 months post-engraftment (n = 2, each condition). The hybrid cell displayed the same CFU growth properties as the human control cells. They grew well in media containing human growth factors or mouse growth factors, supporting the hypothesis that the cells contain only human DNA (Table 1) . Furthermore, the cells from the hybrid-cell CFUs were collected post culture and stained with anti-HLA antibody and anti-H2Kd antibody. The cells were only positive for the human antigen (HLA+H2Kd-) having lost the H2Kd protein during cell culture (data not shown). Therefore culture resulted in the loss of the H2Kd protein as would be expected if the cells did not contain any mouse DNA.
In order to confirm the involvement of donor stem and early progenitor cells, H2Kd+/HLA+ blood cells were collected from the bone marrow of engrafted mice (2 months post transplantation with UCB) and tested in a Long-Term Culture-Initiating Cell (LTC-IC) assay for the detection of stem/early progenitor cells (n = 2, each cell sample). Control cells included Lin-UCB cells Although CD34+ donor cells acquired H2Kd antigen on their surface the CFU-FACS experiment suggests that it is unlikely that CD34+ cells were able to retain the mouse antigens on their surface throughout cell proliferation and maturation. Taken together our data demonstrates that trogocytosis is an ongoing event that occurs in the bone marrow and the long-term engraftment of human blood stem cells in the mouse bone marrow provides for a constant supply of progenitor and maturing human blood cells that are involved in trogocytosis, which is why we can observe hybrid cells 7 months post engraftment.
Studies of Chimera Animals Reveal That Blood Cell Trogocytosis Is Enhanced by the Irradiation Pretreatment of Recipient Mice During Bone Marrow Transplantation
Previous studies have demonstrated that trogocytosis occurs during the formation of the immune synapse during routine immune cell interactions [26] . We have demonstrated that during bone marrow transplantation using an irradiation pre-conditioning the frequency of trogocytosis and the different types of cells involved greatly increases. In order to determine if trogocytosis between blood cells is a result of the irradiation pre-conditioning, we generated chimeric animals from two strains of mice with different MHC haplotypes. C57BL/6 ES cells (H2Kb) marked with enhanced green fluorescent protein (EGFP) transgene (C57BL/6-EGFP) and BALB/c mice (H2Kd). This study allowed for the production of animals with mixed HLA type blood cells without using irradiation. Thus, positive trogocytosis was determined by the presence of EGFP+/H2Kd + cells. Three chimeric mice were chosen based on their range of coat colour chimerism which was 30%, 50% and 80% respectively. Blood cell analysis for all three mice is depicted in Figure 6A . Blood cells and cells from tissues in the chimeric mice displayed a wide range of EGFP signal intensities. In order to detect the low and high expressing cells the voltage for the FACS detector was set to detect and display both low EGFP and high EGFP signals at the expense of keeping the negative cells on the Y-axis (see Materials and Methods for voltage settings). Original FACS plots with percentages of cells are shown along with pictomicrograph representation for positive (weak to strong expressing cells represented in the right side quadrants). IgG-PE isotype control is represented in Figure 6Ai ,ii,iii. Note that EGFP cells can be observed in the IgG-PE isotype control and gives us a clear indication of the chimera contribution from the C57BL/6 blood cells. The blood cell chimerism does not reflect the coat colour chimerism with mice having 51%, 83% and 82.3% C57BL/6-EGFP blood cell contribution, respectively. We did observe hybrid EGFP+H2Kd+ cells, ranging from 13.3% to 16.4% of the total blood cells (Figures 6Aiv,v, vi) . This experiment supports data from the literature stating trogocytosis occurs naturally, with this experiment specifically demonstrating involvement of the class I MHC(H2Kd) antigens. The frequency of trogocytosis in the blood of these chimeras is lower than in the xenograft studies but within the range expected for the previously described role for trogocytosis involvement in immune surveillance. This data indicates that preconditioning radiation used in the bone marrow transplant studies may increase the number of cells involved in trogocytosis.
Trogocytosis Occurs among Non-Blood Cells of the Solid Organs
Since our data has revealed that trogocytosis is more wide spread than previously reported, we sought to investigate if trogocytosis extends to non-blood tissues. The same chimeric animals analysed for blood-based trogocytosis in the previous section were further analysed for non-blood tissue based trogocytosis. Chimeric organs were divided and a portion was fixed for immunohistochemistry while the remaining tissue was treated with collagenase to generate single cells for flow cytometry analysis. Cells were stained for flow cytometry with anti mouse CD45antibody and anti H2Kd antibody. The CD45 antibody allowed us to remove any contaminating blood cells (CD45+) and CD45 negative cells were then analysed for EGFP and H2Kd. The same cytometry settings were used here as used for the blood cell analysis. Figure 6B and the accompanying Table 2 are representative from mouse #2 (50% coat colour chimerism and 80% blood cell chimerism). The total organ chimerism (% EGFP positive cells) is listed in Table 2 Figure 7B,C arrow) . Chimeric lung tissue with no trogocytosis is shown in Figure 7D .
Discussion
Bone marrow transplantation using hematopoietic stem cells is a common procedure used to reconstitute the bone marrow and regenerate the immune system after full or partial myeloablative therapy to eradicate blood based cancers. Despite the widespread use of bone marrow transplants, there have not been any studies investigating the extent of cell fusion or trogocytosis between blood cells of the donor and host in the transplant setting. Because of the numerous reports of cell fusion and particularly fusion between blood cells and non-blood cells we investigated whether blood cells are capable of fusion with each other [13, 27] . Using a standard mouse model for hematopoietic stem cell engraftment we were able to demonstrate that .80% of the donor cells carried recipient surface MHC class I proteins suggesting a fusion event. Further investigation resulted in our concluding that cell-cell fusion was Table 2 . doi:10.1371/journal.pone.0008489.g006 not the mechanism that could account for the high level of transfer nor could other mechanisms such as DNA uptake of apoptotic bodies by phagocytosising cells. The most parsimonious mechanism was trogocytosis.
The potential transfer of mismatched Class I HLA antigens between cells as identified in this study has implications for graft acceptance in the bone marrow transplant setting. Furthermore, in animal studies used to investigate the ability of blood cells to differentiate into non-blood tissues, the determination of successful stem cell differentiation or blood cell transdifferentiation relies heavily on the identification of cell surface markers on the regenerated tissue. Thus, the occurrence of hybrid cells due to cell fusion or surface antigen transfer between blood cells or blood cells and organs needs to be clarified when interpreting differentiation as well as transdifferentiation data. Furthermore, the recent report that the transfer mitochondria occurs between cells without cell fusion indicates that cell-cell interaction involves many novel mechanisms [28] .
In this study we investigated the extent of trogocytosis between donor and recipient blood cells in the bone marrow transplant setting and between blood cells and non-blood cells in chimeric animals. Our study demonstrates that trogocytosis is more common than previously reported [26] . It has been demonstrated by others that dendritic cells, NK cells, T and B-cells are capable of acquiring MHC class1 antigens by trogocytosis at the immunological synapse. Here we have expanded on these studies to investigate the occurrence of surface protein transfer in the xenograft setting and its impact on our understanding of experimental disease models. We have clearly demonstrated that trogocytosis is not limited to antigen presenting cells as all donor hematopoietic blood cells, including the CD34+ stem and progenitor cells, acquired recipient MHC Class I molecules.
Mouse engraftment models have been the standard assay used to identify blood stem cells. Despite the long history of using murine models for intra-species and xenograft transplants, our observation that almost all of the donor blood cells acquired recipient MHC proteins in 100% of the engrafted mice, regardless of time post transplant (t = 7 days to t = 7 months), has not been previously reported. Our NOD/SCID mouse transplant protocol results in low numbers of human antigen presenting T and NK cells and B-cells and therefore, trogocytosis due to immune cell reactions cannot account for all of the events observed in this study [12, 29, 30, 31] . Although there was not a transfer of DNA during trogocytosis, our long-term studies and peripheral blood analysis demonstrate that trogocytosis is an ongoing event and was maintained in the recipient mice for 7 months. FISH analysis, karyotyping and the loss of cell surface markers after in vitro culturing confirmed that trogocytosis and not cell fusion was the cause of hybrid cells in a bone marrow transplant setting. Furthermore, using chimeric animals, we have demonstrated that both blood and non-blood tissues are involved in trogocytosis. Our observation that MHC-Class I antigens are involved implicates potential role of trogocytosis in graft acceptance.
In the bone marrow transplant setting, we were able to demonstrate that trogocytosis occurs in the bone marrow and not the peripheral blood, where the cells find themselves in close contact, a requirement for surface protein transfer. Therefore trogocytosis requires that the donor cells migrate to the bone marrow and engraft. In the clinical setting, trogocytosis would require the presence of recipient cells, a condition that is met in myeloablative conditioning of humans as donor cell infusion occurs before the patient becomes aplastic. Recipient bone morrow cells would also be present to participate in trogocytosis in reduced intensity and non-myeloablative conditioning regimes used for human bone marrow transplants.
Interestingly, our studies indicate that trogocytosis is unidirectional for MHC-Class I antigens, with proteins moving from the recipient cells to the donor cells. The widespread transfer of recipient MHC class1 molecules to donor blood cells and donor organs led us to question if other surface proteins are involved in trogocytosis as well. Recipient (mouse) CD45, but not recipient CD14 or CD41a, could be transferred to donor (human) cells. These observations, along with the chimera studies, demonstrate MHC Class I molecules are routinely transferred in the transplant setting, as are CD45 antigens, although the latter occurs to a lesser extent. Despite the fact that donor stem and progenitor cells (CD34+) are involved in trogocytosis, it is unlikely that these cells are the sole source of hybrid cells. Hematopoietic cells undergo extensive cell division before moving into the circulation and it is unlikely any recipient proteins acquired by trogocytosis at the stem cell level would be present on mature cells.
It has also been demonstrated by others that trogocytosis results in the transfer of proteins that can maintain their function on the receiving cells. For example, there is evidence that HLA-G can be transferred from a tumour cell to a healthy cell, conferring the same NK cell suppression function that it had on the tumour cell [32] and T-cells that acquired CD80 and HLA-DR from antigen presenting cells developed an antigen presenting-cell function [33] . The demonstration that HLA-G or CD80/HLA-DR transfer results in the establishment of function suggests that the transfer of MHC class I proteins from the recipient cells to the donor cells observed in our study may alter the way the donor cell is perceived by the host immune system [34] . We can speculate that the transfer of recipient MHC could confer a 'recipient-self' identity to the donor cells, thus protecting them from immune attack in the bone marrow transplant setting. Support for this hypothesis comes from the demonstration that the genetic regulation of NK cell-mediated rejection of bone marrow grafts is dependent on the MHC class I genes. It has been demonstrated that allogenic grafts are rejected because they fail to express the 'self' MHC recognised by the recipient NK cells. In one study, it was demonstrated that the introduction of a single transgene of the recipient MHC-class I gene into mismatched donor bone marrow cells resulted in the donor cells being able to present as 'self' MHC in the recipient, thereby altering the reaction of NK cells and preventing rejection [34] . Blood cells have therapeutic potential beyond the reconstitution of the bone marrow. Using different animal models of human disease, blood cells have been shown to give rise to neural cells, endothelial cells, striated muscle, hepatocytes and cardiac tissue [35, 36, 37] . It has been suggested that blood cells have the ability to transdifferentiate due to their ability to give rise to nonblood cells such as cardiomyocytes [38] or hepatocytes [3] while other studies have demonstrated that putative transdifferentiation events are actually a result of cell-cell fusion [23, 27] . Transdifferentiation-like events can also be linked to the possible presence of a rare pluripotent embryonic-like stem cell in the blood [39] . While it is possible that transdifferentiation events can be due to one or all of these mechanisms our study indicates that trogocytosis may account for some putative transdifferentiation events involving blood cells.
The chimera mouse model is ideal for the study of trogocytosis as there have been no reports of cell fusion in chimeras [40] . Furthermore, cell fusion that has been observed in the liver between hepatocytes and blood cells is initiated by tissue damage [41] . The lack of any induction of tissue damage in our chimera experiments allowed us to observe trogocytosis only. The data from the chimera studies suggests that blood flow within an organ and not the level of organ chimerism dictates the frequency of trogocytosis as organs with high blood flow had high levels of trogocytosis despite their levels of chimerism. For example liver had only 2% chimerism (2% EGFP+ cells) but 50% of these cells were involved in trogocytosis (EGFP+/H2Kd+) versus the spinal cord with 33% chimerism but only 1% of these cells were also H2Kd+. It is evident that trogocytosis is becoming an important mechanism to consider for normal immune reactions, organ and bone marrow transplantation and experimental animal models for cell differentiation.
Materials and Methods
Ethics Statement
Collection of all human tissue samples were approved by the Research Ethics Boards of the University of Toronto and Mount Sinai Hospital, Toronto, Canada. Patients were required to read a patient information sheet and sign a consent form prior to any samples being collected. All samples were anonymous.
All animal studies were approved by the animal ethics board at Mount Sinai Hospital (AUP# 09-12-0021a-H).
Blood Collection, Processing and Cryopreservation
Qualified hospital personnel, following protocols approved by the human ethics committee of the Mt. Sinai Hospital and the University of Toronto, collected the cord blood at the time of delivery. The BM or UCB samples were screened for HIV I/II, HTLV-I/II, Hepatitis B (HBs Ag), Hepatitis C (anti HVC), CMV and VDRL and written consent for collecting and processing umbilical cord blood was obtained at the time of registration.
The blood volume was reduced and the red blood cells removed with Pentaspan (starch) (DuPont, USA) as described previously [37] . All samples were cryopreserved prior to use by storage in liquid nitrogen.
Isolation of an Enriched Stem Cell or Progenitor Cell Population
Human UCB or BM were used fresh or thawed and diluted drop wise in 106volume, pelleted and resuspended in 0.1% BSA/ HBSS. Lin-cells were isolated using a negative selection column according to the manufacturer's instructions (StemCell Technologies, Canada). The antibody mix contained a set of lineage specific surface markers found on mature hematopoietic cells; CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66 and glycophorin A. Following isolation, the Lin-cells or the Lin+ cells were used directly in the SRC-assay.
Long Term Cell-Initiating Cell Assay (LTC-IC) Repopulating Assay and Colony Forming Unit Assay (CFU)
A pre-made methylcellulose based colony assay medium (Stem Cell Technologies, Canada) was used as described by the manufacturer. The medium is formatted to grow mouse (M3434) or human (H4344) primitive progenitors. Total nucleated cells from bone marrow aspirates were stained with antibodies to H2Kd and HLA-ABC and sorted by flow cytometry. Sorted cells were plated at 5000 and 2000 cells per 3 ml of medium. All populations were plated in duplicate and scored at days 12, 14, 16 and 18. Day 16 data is represented in Table 1 . Cells were also tested for primitive progenitor cells by LTC-IC protocol as described by the manufacturer (Stem Cell Technologies, Canada). Briefly, cells were plated on M2-10B4 fibroblasts (Stem Cell Technologies, Canada) and cultured for 5 weeks with half medium changes weekly. Cells were then collected and plated in a CFU assay (H4344) and scored at day 18 for colonies.
NOD.CB17-Prkdc SCID Mouse Engraftment
Non-obese severe combined immune deficient NOD.CB17-Prkdc SCID mice (Jackson Labs, Bar Harbour, Maine, USA) were used to test the engraftment potential of human blood cells [24] . All experiments followed established protocols and received animal ethics approval at Mt. Sinai Hospital. The mice were irradiated 2 hours before engraftment at 360 Rads using a Cs 137 source. The mice were then injected via the tail vein with 100 ml of cell solution. Survival rate was .80% per experiment. At different time intervals, animals were euthanized and the bone marrow was flushed from the femurs. Cells were washed in PBS and the cell pellets were subjected to Red Blood Cell Lysis Buffer for 3 minutes and washed again.
Flow Cytometry
A: Bone marrow analysis. Mice were sacrificed from 7 days to 7 months post transplantation, the femurs excised and flushed using 1 ml of PBS containing 2% FBS (2% FBS/ PBS). Cells were treated with RBC Lysis Buffer and washed once with 2% FBS/PBS and pelleted. The cell pellet was resuspended at 1 million cells/ml and immunostained. After the antibody was added, cells were incubated on ice for 30 min. washed twice in 2% FBS/PBS and resuspended at 1 million cells per 0.2 ml and immediately analysed by flow cytometry with a Coulter-Epics Flow cytometer (Coulter, Burlington, Canada). Isotype controls were used in all cases. Peripheral blood was collected for analysis by heart puncture before bone marrow was collection.
B: Chimera analysis. To generate single cell suspensions from mouse organs, mice were perfused with 5% FBS/HBSS and the organs dissected and minced on ice. These minced tissues were washed with PBS and incubated at 37uC in an enzyme solution containing 1.5 mg/ml collagenase + 0.25% trypsin in PBS for 10-30 minutes depending on the size of the tissue fragment. After incubation, DMEM containing 5% FBS was added to the tissues that were then triturated with a large bore pipette so not to shred the cells. The large fragments were allowed to settle (30 sec) and the single cells in suspension were collected. This single cell suspension was passed through a 70 micron mesh filter and at this point was ready for FACS immunostaining as outlined above. The range of EGFP fluorescence intensity in chimeric mice was variable, so in order to clearly display the full range of EGFP expressing cells required that the detectors for EGFP were set to capture and display all EGFP positive cells at the expense of the negative cells being pushed up against the Y-axis. Original histograms displaying percentages of cells for each quadrant are shown in the figures. The settings for the detectors are shown in Table 3 .
Antibodies
Primary antibodies used: H2Kd (BD-Pharmingen, USA), mouse CD45 (BD-Pharmingen, USA), human CD45 (J33) (Immunotech, France), HLA-ABC (Immunotech, France), human CD34 (Immunotech, France), mouse CD14 (BD-Pharmingen, USA), human CD14 (Immunotech, France), mouse CD41a (BD-Pharmingen, USA), human CD41a (BD-Pharmingen, USA). Secondary antibodies conjugated with Alexafluor 596 (Red) or Alexafluor 488 (Green) were used.
Fluorescent In-Situ Hybridization
Pan centromeric chromosome paint for human (cat# 1695) and mouse (cat# 1697) from StarFISH (Cambio, England) was used for fluorescent in-situ hybridization (FISH). Cells were fixed in 3:1 ethanol:acetic acid, dehydrated in an ethanol series, mounted on slides and air dried FISH was performed according to the manufacturer's protocol (StarFISH, Cambio, England).
Chimera Production
Fluorescent variants of C2-C57BL/6NTac ES cells were generated by the random integration of EGFP transgene driven by a CMV immediate early enhancer coupled to the chicken bactin promoter and first intron (pCAG) using co-electroporation with a circular selectable marker pPGK Puro using standard ES cell culture protocols [42] . Chimeric mice were produced by aggregation of C57BL/6 EGFP ES cell line #12 with BALB/ cAnNCrl morula stage embryos as described [42, 43] . Chimeras were identified by a mixed black and albino coat colour. Chimeras were sacrificed at 8-weeks of age and tissues were processed for immunohistochemistry or flow cytometry.
Immunohistochemistry
Tissues were fixed in 10% buffered formalin (Fisher Scientific, USA) for 120 min, at 4uC, washed in PBS (Phosphate Buffered Saline), stored in 70% ethanol, dehydrated in graded ethanol series, cleared in toluene, immersed in paraffin at 65uC, embedded into paraffin blocks and sectioned into 5 mm sections. Sections were deparaffinized 265 min in xylene. Nonspecific binding was blocked with 10% serum in PBS containing 0.1% Triton X-100 (Sigma, USA) for 240 min at room temperature, followed by a brief wash in PBS. Primary antibody was applied (solution 1:50-1:100) for overnight incubation at 4uC. Untreated mouse tissue sections and sections with omitted primary or secondary antibody were used as negative controls. The slides were washed 5615min in PBS, the secondary antibody was applied at 1:200 dilution for 60 min at room temperature, and then washed again 6615 min in PBS. Finally, the slides were mounted in 50% glycerol in PBS with DABCO (Sigma, USA) at 100 mg/ml.
The slides were examined on a Zeiss Axioplan Photomicroscope equipped with epifluorescent ultraviolet light and corresponding excitation and barrier filters. Pictures were taken on a Delta Vision wide-field, optical sectioning microscope workstation capable of recording three-dimensional images of fluorescently labelled specimens (Issaquah, Washington). The station includes: an Olympus IX-70 inverted fluorescence microscope with custom optical filters, and precision XYZ motorized stage, O2 Silicon Graphics computer work station with image collection and deconvolution software. 
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